Valsartan + Sacubitril Tablets

Therapeutic Indication

Heart failure with reduced ejection fraction (HFrEF)

Reduction of cardiovascular mortality and hospitalization in chronic heart failure

Adjunct therapy in patients intolerant to ACE inhibitors

+91 85919 78885

Valsartan + Sacubitril

Tablet

This fixed-dose combination (ARNI) is used in the management of heart failure with reduced ejection fraction (HFrEF). Valsartan, an angiotensin receptor blocker (ARB), reduces vasoconstriction and aldosterone effects, while Sacubitril, a neprilysin inhibitor, enhances natriuretic peptides, leading to vasodilation, natriuresis, and reduced cardiac remodeling.

Speciality	Cardiology \| Heart Failure Management \| Internal Medicine
Tags	Heart Failure \| ARNI \| Valsartan \| Sacubitril \| Cardioprotection
Strength	Valsartan 26 mg Sacubitril 24 mg
Packing Size	10 Tablets

Check all Tablet Range

Click to know More

Mechanism

Valsartan: Blocks angiotensin II AT1 receptors → vasodilation, reduced aldosterone secretion, decreased blood pressure.
Sacubitril: Inhibits neprilysin → increases levels of natriuretic peptides → vasodilation, natriuresis, diuresis, and reduced cardiac remodeling.

Pharmacokinetics

Absorption: Both well absorbed orally; peak plasma levels in 1–2 hrs.
Distribution: Valsartan highly protein bound (~95%); Sacubitril moderately bound.
Metabolism: Sacubitril converted to active metabolite LBQ657; Valsartan minimally metabolized.
Excretion: Valsartan via feces; Sacubitril metabolite via urine.
Half-life: Valsartan ~9 hrs; LBQ657 ~11 hrs.

Side Effects

Hypotension
Hyperkalemia
Cough
Dizziness
Rare: Angioedema

Contraindication

History of angioedema with ACE inhibitors or ARBs
Pregnancy
Severe hepatic impairment

Interaction

Potassium-sparing diuretics ↑ risk of hyperkalemia
NSAIDs may reduce antihypertensive effect
Do not combine with ACE inhibitors (↑ risk of angioedema)

Warning and Precautions

Monitor blood pressure, renal function, and potassium levels
Discontinue ACE inhibitors at least 36 hrs before starting therapy
Use cautiously in renal impairment

Dosage

As directed by the Physician.

All product details on this website are for reference and informational purposes only and are not directed at patients or consumers.
As a contract manufacturer, DM Pharma Pvt Ltd is not responsible for the marketing or end use of these products and disclaims all liability arising from reliance on this information.
Please consult a healthcare professional before using any medicinal product.